1. Letter: lipid‐lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B—more evidence is needed. Authors' reply. Issue 8 (13th September 2017) Authors: Shaheen, A. A.; Al‐Mattooq, M.; Yazdanfar, S.; Burak, K. W.; Swain, M. G.; Congly, S. E.; Borman, M. A.; Lee, S. S.; Myers, R. P.; Coffin, C. S. Journal: Alimentary pharmacology & therapeutics Issue: Volume 46:Issue 8(2017) Page Start: 770 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers. Issue 6 (13th July 2017) Authors: Shaheen, A. A.; AlMattooq, M.; Yazdanfar, S.; Burak, K. W.; Swain, M. G.; Congly, S. E.; Borman, M. A.; Lee, S. S.; Myers, R. P.; Coffin, C. S. Journal: Alimentary pharmacology & therapeutics Issue: Volume 46:Issue 6(2017) Page Start: 599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗